Here are complete model answers for all questions, based primarily on Park's Textbook of Preventive and Social Medicine.
Q.1 Rabies (3+3 marks)
a) Categorize Animal Bite Exposures as per Latest WHO Guidelines
WHO classifies rabies exposures into 3 categories:
| Category | Type of Contact | Action Required |
|---|
| I | Touching/feeding animals; licks on intact skin | No PEP required |
| II | Nibbling of uncovered skin; minor scratches/abrasions without bleeding; licks on broken skin | Wound treatment + Vaccine |
| III | Single/multiple transdermal bites or scratches; contamination of mucous membrane with saliva (licks); all bat exposures; contact with animals of Category 2/3 in endemic area | Wound treatment + Vaccine + Rabies Immunoglobulin (RIG) |
All Category II & III exposures require immediate wound treatment (soap + water wash for 15 min, then virucidal agent - povidone iodine/alcohol).
b) Current Schedule of Intra-Dermal Rabies Vaccination (IDRV) for Post-Exposure Prophylaxis
The Updated Thai Red Cross (TRC) / WHO-recommended ID schedule currently used in India:
2-Site ID (2-2-2-0-2) Schedule:
- Day 0: 0.1 mL ID at 2 sites
- Day 3: 0.1 mL ID at 2 sites
- Day 7: 0.1 mL ID at 2 sites
- Day 14: 0.1 mL ID at 2 sites (some schedules omit)
- Day 28/30: 0.1 mL ID at 1–2 sites (booster)
RIG (Rabies Immunoglobulin): For Category III - Human RIG (HRIG) 20 IU/kg body weight OR Equine RIG (ERIG) 40 IU/kg body weight, infiltrated at wound site on Day 0. Do not delay vaccine while waiting for RIG.
Key advantages of ID route: Saves vaccine (uses 0.1 mL vs 0.5-1.0 mL IM), cost-effective, equally immunogenic.
Previously vaccinated persons: Only 2 doses ID on Days 0 and 3 - NO RIG required.
Q.2 HIV in 28-Year-Old Pregnant Woman (3+3 marks)
a) Describe Public Health Measures to Prevent Mother-to-Child Transmission (MTCT)
Under India's PPTCT Programme (Prevention of Parent-to-Child Transmission):
- Universal HIV counselling and testing - Routine offer of HIV test to ALL pregnant women at ANC with "opt-out" approach; done at ICTCs
- Lifelong ART for all HIV+ pregnant women - TDF + 3TC + EFV (triple drug regimen) regardless of CD4 count or WHO clinical stage (Option B+), both for maternal health and prevention of vertical transmission
- Safe obstetric practices - Institutional deliveries; avoid unnecessary episiotomy, invasive monitoring, prolonged rupture of membranes
- Infant prophylaxis - Nevirapine syrup given to the newborn for 6 weeks
- Infant feeding counselling - Exclusive breastfeeding for 6 months while on ART OR replacement feeding if safe/affordable/feasible/sustainable/accessible (AFASS criteria)
- Family-centric approach - Involve spouse/partner for testing; prevent re-infection
- Co-infection management - Treat STIs, TB, and opportunistic infections
- Nutritional and psychosocial support
b) Explain Role of National AIDS Control Programme in Management
Under NACP IV (National AIDS Control Programme):
- More than 15,000 ICTCs provide PPTCT services nationwide
- Frontline health workers (ANMs) conduct community-based HIV screening at sub-centre level
- ART centres provide free lifelong triple-drug ART
- HIV-exposed infants receive Early Infant Diagnosis (EID) via DNA-PCR at 6 weeks
- Linkage to care: HIV+ mother linked to ART centre; infant followed up at 18 months for confirmatory antibody testing
- Prevention of new infections through IEC/BCC campaigns, targeted interventions for high-risk groups
Q.3 30-Year-Old Man with >5 Hypo-Pigmented Patches (2+4 marks)
Diagnosis (2 marks)
Multibacillary (MB) Leprosy (Lepromatous type or BL/LL spectrum)
Basis of diagnosis:
- More than 5 hypo-pigmented (anaesthetic) skin patches - cardinal sign of leprosy
- Per WHO field criteria: >5 skin lesions = Multibacillary leprosy
- Confirm with: skin smear for AFB (positive in MB), skin biopsy
Cardinal signs of leprosy (any 1 = diagnosis):
- Hypo-pigmented/erythematous skin patches with loss of sensation
- Thickened/enlarged peripheral nerves
- Positive skin smear for AFB
Management as per National Leprosy Eradication Programme (4 marks)
MDT (Multi-Drug Therapy) for Multibacillary Leprosy (MB-MDT):
| Drug | Dose | Supervision |
|---|
| Rifampicin | 600 mg once a month (adults) / 450 mg for children <10 yr | Supervised |
| Dapsone | 100 mg daily (adults) / 50 mg daily for children | Self-administered |
| Clofazimine | 300 mg once a month + 50 mg daily (adults) | Monthly dose supervised |
Duration: 12 monthly blister packs, to be completed within 18 months
Additional management:
- Provide pre-packed MDT blister packs free of charge under NLEP via PHC/CHC
- Disability assessment at start and end of treatment
- Lepra reaction management:
- Type 1 (Reversal Reaction): Prednisolone 40-60 mg/day, continue MDT
- Type 2 (ENL): Thalidomide / Prednisolone / Clofazimine, continue MDT
- Physiotherapy and self-care to prevent deformities
- Social rehabilitation, counselling to reduce stigma
- Contact examination of household contacts annually
Note: MDT continues even during pregnancy (safe) and in HIV co-infection.
Q.4 Short Notes (Any 3 out of 4) - (3×6=18 marks)
1. Disability-Adjusted Life Year (DALY)
Definition: DALY is a measure of the burden of disease in a population. It represents the number of years of healthy life lost due to ill-health, disability, or early death.
Formula:
DALY = YLL + YLD
- YLL (Years of Life Lost) = due to premature mortality
- YLD (Years Lived with Disability) = due to disability/morbidity
One DALY = one year of healthy life lost
Components:
- YLL = N × L, where N = number of deaths and L = standard life expectancy at age of death
- YLD = I × DW × L, where I = incidence, DW = disability weight (0–1), L = average duration
Uses:
- Measures overall disease burden in a population
- Compares burden of different diseases
- Priority-setting for health interventions and resource allocation
- Used in Cost-Effectiveness Analysis (CEA) as cost per DALY averted
Example: A country reporting 500 DALYs per 1000 population for TB indicates 500 healthy years lost per 1000 people due to TB.
2. Consequences of Failure to Disclose Medical Errors
Definition: Medical error is a preventable adverse event resulting from care provided to a patient, not due to the underlying disease.
Consequences of NON-DISCLOSURE:
A. For the Patient:
- Continued harm from unrecognized/uncorrected error
- Loss of trust in the healthcare system
- Unable to make informed decisions about alternative treatment
- Denied legal recourse or compensation
- Psychological harm - anxiety, anger when truth later discovered
B. For the Healthcare Provider:
- Ethical violation (breaches principle of veracity/transparency)
- Increased risk of litigation (cover-up is legally far worse)
- Loss of professional credibility
- Psychological burden - guilt, moral injury, burnout
- License/disciplinary action if concealment discovered
C. For the Healthcare System/Society:
- Errors not analyzed = errors repeat (no system learning)
- No quality improvement possible without error reporting
- Erosion of public trust in health institutions
- Increased healthcare costs from prolonged treatment of unresolved errors
- Undermines patient safety culture
Ethical basis for disclosure: Principles of autonomy, non-maleficence, beneficence, justice, and veracity all mandate honest communication of errors.
3. Confounding Factor and Bias in Epidemiological Studies
BIAS:
Definition: A systematic error in study design, data collection, or analysis that leads to an incorrect estimate of the true association between exposure and disease.
Types:
- Selection Bias - Systematic error in selecting study subjects (e.g., Berkson's bias, Neyman bias, Volunteer bias)
- Information/Measurement Bias - Error in classifying exposure or outcome
- Recall bias: Cases remember past exposure more than controls
- Observer bias: Investigator's knowledge influences data collection
- Confounding bias - (see below)
CONFOUNDING:
Definition: Confounding occurs when a third variable (confounder) is associated with both the exposure and the outcome, and distorts the true relationship between them.
Criteria for a confounder:
- Must be associated with the exposure
- Must be an independent risk factor for the disease
- Must NOT be on the causal pathway between exposure and disease
Example: In studying coffee-smoking-lung cancer relationship: Smoking is a confounder - it is associated with coffee drinking AND is independently a cause of lung cancer.
Control of confounding:
- At design stage: Randomization, Matching, Restriction
- At analysis stage: Stratification (Mantel-Haenszel), Multivariate analysis, Standardization
4. Role of Family in Health and Disease (Describe with Suitable Examples)
Family as the basic unit of society plays critical roles in health:
A. In Health Promotion:
- Healthy lifestyle habits (diet, exercise, hygiene) are shaped within the family
- Immunization decisions are family decisions
- Example: A family that maintains hand hygiene reduces diarrheal disease burden
B. In Disease Prevention:
- Genetic counseling and carrier detection (e.g., sickle cell, thalassemia)
- Early identification of symptoms and health-seeking behavior
- Example: Family history of diabetes prompts early screening in offspring
C. In Disease Causation (Family as a risk unit):
- Communicable diseases spread within families (TB, COVID-19, cholera)
- Genetic diseases cluster in families (hypertension, cancer)
- Behavioral risks - alcoholism, domestic violence, tobacco use
- Example: TB contact tracing is done within the family
D. In Care and Rehabilitation:
- Family provides physical, emotional, and financial support during illness
- Adherence to treatment (e.g., DOTS supervision by family member)
- Example: Caregiver in the family critical for stroke rehabilitation
E. Family Life Cycle and Health:
- Different stages (marriage, childbirth, aging) bring specific health challenges
- Family planning services target the family unit
Family Health Approach (7×7 Matrix by ICMF) is used to identify family health problems at each stage of family life cycle.
5. 7×7 Strategy of Anaemia Mukt Bharat (AMB)
Anaemia Mukt Bharat (AMB) was launched in 2018 under the National Nutrition Mission (POSHAN Abhiyaan) with the target of reducing anaemia prevalence by 3 percentage points per year among target beneficiaries.
The 7×7 Strategy:
7 Target Beneficiary Groups:
- Children 6–59 months
- Children 5–9 years
- Adolescent girls and boys (10–19 years)
- Pregnant women
- Breastfeeding women
- Women of reproductive age (15–49 years, non-pregnant, non-lactating)
- Elderly (60+ years)
7 Interventions:
- Prophylactic Iron and Folic Acid (IFA) supplementation - across life stages
- Deworming - biannual deworming for children and adolescents
- Intensified year-round IFA supplementation - using platform-based delivery (schools, AWCs)
- Mandatory IFA fortification of rice - supplied through PDS/mid-day meal
- Delayed cord clamping - at least 3 minutes at birth (for newborns)
- Treatment of moderate/severe anaemia at health facilities
- Behavioural change communication - to improve dietary diversification, address compliance issues
Delivery Platforms used: ICDS (AWCs), schools, health facilities, ASHA/ANM
Target: Reduce anaemia prevalence in all target groups by 3% per year, achieving anaemia-free India.
All answers based on Park's Textbook of Preventive and Social Medicine (PSM).